Clinical trials: Metastatic Malignant Neoplasm
Metastatic Breast Cancer, Metastatic Colon Cancer
Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients
The Wnt proteins belong to a family of proteins that have been demonstrated to play a role in the formation and dissemination of tumours.
- Conditions
- Metastatic Breast Cancer, Metastatic Colon Cancer, Metastatic Prostate Cancer
- Trial name
- NCT02655952
- Testing
- Foxy-5
- Where
- 4 sites in Denmark, United Kingdom
- Volunteers
- 17 people
- Sponsor
- WntResearch AB
Post Menopausal Breast Cancer
Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
This international, multi-center, open-label, single-arm study evaluated the safety and tolerability profile of everolimus in post-menopausal women with HR positive, HER2 negative locally advanced or metastatic breast cancer…
- Trial name
- EVEREXES (NCT03176238)
- Testing
- everolimus, exemestane
- Where
- 55 sites in Australia, India and 11 more
- Volunteers
- 235 people
- Sponsor
- Novartis Pharmaceuticals
Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma
Expanded access use of INCB054329 to treat a single patient with metastatic renal cell carcinoma.
- Trial name
- NCT03896815
- Testing
- INCB054329
- Sponsor
- Incyte Corporation
Advanced Solid Tumors
HV-101 for Patients With Advanced Solid Tumors
Background: Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to treat patients.
- Trial name
- NCT05868915
- Testing
- HV-101
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Hervor Therapeutics
Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
The aim of this adaptive Phase 3 trial is to show a statistically significant superiority of EndoTAG-1 in combination with gemcitabine compared to gemcitabine monotherapy in patients with locally advanced/metastatic pancreatic…
- Conditions
- Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT03126435
- Testing
- EndoTAG-1, Gemcitabine
- Where
- 68 sites in United States, France and 5 more
- Volunteers
- 218 people
- Sponsor
- SynCore Biotechnology Co., Ltd.
Ovarian Neoplasms, Fallopian Tube Neoplasms
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers.
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
- Trial name
- FRAmework-01 (NCT07213804)
- Testing
- Sofetabart Mipitecan, Paclitaxel, Topotecan
- Where
- 265 sites in United States, Australia and 25 more
- Volunteers
- 1,630 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Squamous Cell of the Head and Neck
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN® therapeutic reovirus in combination with Paclitaxel and Carboplatin is effective and safe in the treatment of squamous cell…
- Trial name
- NCT00753038
- Testing
- REOLYSIN®, Carboplatin, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Oncolytics Biotech
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
The main purpose of this study is to evaluate the effectiveness of S-1 and oxaliplatin with or without ramucirumab as first line therapy in participants with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Trial name
- NCT02539225
- Testing
- Ramucirumab, S-1, Oxaliplatin
- Where
- 34 sites in Japan, South Korea and 1 more
- Volunteers
- 191 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in…
- Trial name
- NCT06478693
- Testing
- MT-303, MT-303 +Atezolizumab + Bevacizumab
- Where
- 9 sites in Australia, South Korea and 1 more
- Volunteers
- 70 people
- Sponsor
- Myeloid Therapeutics
Breast Cancer
Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
RATIONALE: Estrogen can stimulate the growth of cancer cells. Letrozole may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00014638
- Testing
- letrozole
- Where
- 20 sites in United States
- Sponsor
- Novartis
Metastatic Colorectal Cancer
Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer
The primary purpose of this study is to evaluate the clinical response and safety of CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type…
- Trial name
- CRC009 (NCT01550055)
- Testing
- CMAB009 plus Irinotecan, Irinotecan-only and sequential-CMAB009
- Volunteers
- 512 people
- Sponsor
- Shanghai Zhangjiang Biotechnology Limited Company
Metastatic Castration-resistant Prostate Cancer (mCRPC)
GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)
The purpose of this clinical trial is to evaluate the safety, tolerability, and preliminary anti-cancer activity of GI-102 in combination with pasritamig in adult men with metastatic castration-resistant prostate cancer (mCRPC)…
- Trial name
- NCT07871435
- Testing
- GI-102, Pasritamig
- Where
- 6 sites in United States, South Korea
- Volunteers
- 107 people
- Sponsor
- GI Innovation, Inc.
Gastric Cancer
Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients
To assess the efficacy of olaparib when given in combination with paclitaxel compared with paclitaxel alone as defined by progression-free survival (PFS), in all patients with recurrent and metastatic gastric cancer who progress…
- Trial name
- NCT01063517
- Testing
- olaparib, paclitaxel
- Where
- 7 sites in South Korea
- Volunteers
- 124 people
- Sponsor
- AstraZeneca
Breast Neoplasms
A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer
To assess progression-free survival at the combination dose determined in the Phase 1 portion of the study, and safety of sunitinib combined with exemestane in patients with metastatic or locally-recurrent, unresectable breast…
- Trial name
- NCT00417885
- Testing
- exemestane, sunitinib malate
- Where
- 3 sites in United States, Canada
- Volunteers
- 6 people
- Sponsor
- Pfizer
Head and Neck Squamous Cell Carcinoma
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent…
- Trial name
- NCT06496178
- Testing
- Petosemtamab, Investigator's Choice
- Where
- 193 sites in United States, Argentina and 22 more
- Volunteers
- 621 people
- Sponsor
- Genmab
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer
To evaluate efficacy and safety of irinotecan hydrochloride liposome in combination with 5-FU/LV as second-line treatment for locally advanced or metastatic pancreatic cancer after treatment failure with gemcitabine-based therapy.
- Trial name
- NCT05074589
- Testing
- Irinotecan liposome、5-Fluorouracil、Leucovorin
- Where
- China
- Volunteers
- 298 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Castration-Resistant Prostatic Cancer
Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
This observational prospective single arm cohort study is designed to assess pain and bone pain related quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium-223 in a real life…
- Trial name
- PARABO (NCT02398526)
- Testing
- Radium-223 dichloride, (Xofigo, BAY88-8223)
- Where
- Germany
- Volunteers
- 363 people
- Sponsor
- Bayer
HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
This is a Phase Ib, open-label, two-stage study with two active regimens in each stage designed to evaluate the safety and tolerability of combination treatment with atezolizumab, trastuzumab, and pertuzumab (with and without…
- Conditions
- HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer, Locally Advanced or Early Breast Cancer
- Trial name
- NCT02605915
- Testing
- Atezolizumab, Carboplatin, Docetaxel
- Where
- 20 sites in United States
- Volunteers
- 98 people
- Sponsor
- Hoffmann-La Roche
Non-squamous Non-small Cell Lung Cancer
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally…
- Trial name
- NCT06627647
- Testing
- Rilvegostomig, Pembrolizumab, Carboplatin
- Where
- 301 sites in United States, Argentina and 23 more
- Volunteers
- 1,160 people
- Sponsor
- AstraZeneca
Advanced Cancer, Metastatic Cancer
A Study of LY3023414 in Participants With Advanced Cancer
The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer.
- Conditions
- Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer
- Trial name
- NCT01655225
- Testing
- LY3023414, Midazolam, Fulvestrant
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 156 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.